Replies to post #349 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

Additional commentary on RVNC/MYL deal:

The launch of the $MYL/ $RVNC Botox-biosimilar program makes it crystal clear that both companies consider $RVNC's RT002 to be well differentiated from Botox. https://t.co/L72NdtJkl5

— Roy Friedman (@DewDiligence) March 1, 2018

https://twitter.com/DewDiligence/status/969233483322281984

[DewDiligence]

Re: Amendment to RVNC-MYL Botox-biosimilar agreement

https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929019000098/rvncaugust2220198-k.htm

RVNC receives a $5M* non-refundable cash payment from MYL immediately as compensation for allowing MYL until 4/30/20 to decide whether to opt in on the Botox-biosimilar program. (4/30/20 should be after MYL closes its deal with PFE on the Upjohn-related merger.)

The amended RVNC-MYL agreement retains in full RVNC's potential $100M in clinical/regularatory milestones and $225M in sales milestones (#msg-138921254).

*In addition to the $25M up-front payment RVNC received in early 2018.